Clinical research progress of targeted therapy for atherosclerotic cardiovascular disease
Dong Huisheng
Sun Jiefang
Wang Bailin
Xing Haoyu
Gao Qianlong
Pan Qifei
Ma Qian
Yu Yang
Li Ying
Abstract：Atherosclerotic cardiovascular disease(ASCVD)is the leading cause of death worldwide.With the aging of population,the incidence and mortality of cardiovascular disease in China continue to increase.Currently,there are still great challenges in non-invasive screening and effective treatment for ASCVD high-risk population.In the past decade,innovative therapies such as monoclonal antibodies and RNA interference drugs have entered clinical application,providing more effective interventions for ASCVD targeted lipid-lowering and anti-inflammatory treatment.At the same time,biomimetic drugs and nano-agents for ASCVD diagnosis and treatment have successively entered clinical research and made breakthrough progress.This article reviews the clinical application progress of innovative drugs such as monoclonal antibodies and RNA interference in the targeted lipid-lowering and anti-inflammatory treatment of ASCVD in recent years,and summarizes the research progress of innovative drug preparations based on nano-delivery systems for the targeted diagnosis and treatment of ASCVD.
Keywords：AtherosclerosisTargeted lipid-lowering and anti-inflammatory therapyNano-delivery systemMonoclonal antibodies
Publication Date：2024-08-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 1246-1249 )